Abstracts tagged "inflammation and positron emission tomography (PET)"

Abstract Number: 1286 • 2016 ACR/ARHP Annual Meeting
Inflammatory Activity of IgG4-Related Disease Lesions Assessed By Quantitative Positron Emission Tomography Correlates with Circulating Plasmablasts Levels
Alvise Berti¹, Carla Canevari², Francesca Gallivanone³, Marco Lanzillotta⁴, Emanuele Bozzalla Cassione⁴, Corrado Campochiaro⁵, Giuseppe Alvise Ramirez⁴, Maria Grazia Sabbadini⁴ and Emanuel Della Torre⁴, ¹Internal Medicine and Clinical Immunology, Vita-Salute San Raffaele University, Milan, Italy, ²Nuclear Medicine, San Raffaele Scientific Institute, Milan, Italy, ³Consiglio Nazionale delle Ricerche, IBFM, Milan, Italy, ⁴Unit of Medicine and Clinical Immunology, San Raffaele Scientific Institute, Milan, Italy, ⁵San Raffaele Scientific Institute, Milan, Italy
Background/Purpose: 18-Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) scan is emerging as a promising imaging technique for diagnosis and staging of IgG4-RD. We aim to correlate…
Abstract Number: 2029 • 2015 ACR/ARHP Annual Meeting
Fever of Unknown Origin (FUO) and Inflammation of Unknown Origin (IUO): Is 18f-FDG-PET/CT a Useful First Line Diagnostic Strategy?
Verena Schönau¹, Kristin Vogel², Matthias Englbrecht³, Bernhard Manger³, Daniela Schmidt⁴, Torsten Kuwert⁴ and Georg Schett², ¹Department of Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Clinic of Nuclear Medicine, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: FUO and IUO are rare but diagnostically challenging clinical problems. Because of the abundance of differential diagnoses, a generally accepted diagnostic guideline has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].